Bridgebio Pharma LLC and Bridgebio Pharma, Inc. Transfers Shares of BridgeBio Oncology Therapeutics Inc (BBOT) — SEC Form 4, Oct 16, 2025

SEC Form 4 · No Market Transaction

Other Transaction

Non-market transaction reported.

Reporting Owners

Bridgebio Pharma LLC

10%+

Bridgebio Pharma, Inc.

10%+

TXN 2025-10-10 · FILED 2025-10-16

Equity Position 14.6M sh 13,805,126 → 14,589,846

Equity Change +5.7% shares held after vs before

Filing Lag 3 business days late vs 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

BridgeBio Oncology Therapeutics Inc

BBOT CIK 0001869105

Reporting Owners

Name	Relationship
Bridgebio Pharma LLC CIK 0002076615	10% Owner
Bridgebio Pharma, Inc. CIK 0001743881	10% Owner

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common StockF1 F2 F3	2025-10-10	J - Other	784,720 A		—	14,589,846	Direct

Footnotes (3)

F1: Shares issued pursuant to an amendment to the Transition Services Agreement dated August 11, 2025 in exchange for additional financial and accounting support services provided through December 31, 2025. Show more
F2: Shares are held by BridgeBio Pharma LLC ("BBIO LLC"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. ("BBIO"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collectively, the "BBIO Directors"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any. Show more
F3: (Continued from Footnote 2) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Show more

5%+ Holders · 13D/G 7 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at BridgeBio Oncology Therapeutics Inc

GET /v1/forms/4/0001193125-25-241634 API docs